95% CI 1.63-4.16; p<0.001) were significant predictive factors of PSM. Conversely, hilar clamping, robotic versus open approach and PADUA score were significantly associated with PSM, but were not independent at multivariable analysis.
INTRODUCTION AND OBJECTIVES:
Although platelet count is a well described risk factor for progression of other cancers, the prognostic value has not been described for non-metastatic renal cell carcinoma (RCC). The purpose of this study was to evaluate the association of preoperative platelet count with recurrence in high risk non-metastatic RCC following surgery at 3 institutions.
METHODS: Clinical and pathologic data was collected from !pT3a non-metastatic RCC patients treated surgically at 3 independent centers from 2000-2016. Univariate and multivariate Cox proportional hazard models were used to identify associations of recurrence with preoperative platelet count or other reported risk factors.
RESULTS: Of 1,074 patients at 3 institutions, 278 (25.9%) had RCC recurrence at median of 9.9 months (IQR 4.3-21.1) following attempted curative surgery. Median overall follow-up for patients without recurrence was 19.3 months (IQR 4.6-49.0). Data for preoperative platelet count was available for 98% of patients.
Platelet count as a continuous variable was associated with recurrence in each cohort on independent analysis (p [0.002, p[0.003, p[0.006) . Cut point analysis was performed and PC >250K was chosen as a dichotomous variable associated with risk of recurrence (HR 1.8, 95%CI 1.4-2.3, p<0.001).
Using combined population (n[1074), a multivariate Cox model evaluated the association of recurrence with platelet count >250K or other independent prognostic factors including: nuclear grade, tumor diameter, sarcomatoid features, preoperative hemoglobin, and presence of tumor thrombus. Platelet count >250K was independently predictive of recurrence (HR 1.5, 95%CI 1.1-2.0, p[0.01).
CONCLUSIONS: Elevated preoperative platelet count is independently predictive of recurrence in high risk RCC patients. Integration of platelet count into risk stratification models may help identify patients who benefit from adjuvant therapy or clinical trial enrollment.
Source of Funding: none

PD46-07 SURVIVAL OUTCOMES OF RADICAL VERSUS PARTIAL NEPHRECTOMY IN PT3 PATHOLOGICALLY UPSTAGED RENAL CELL CARCINOMA
Eric Gourley*, Hanzhang Wang, Deepak Pruthi, Dharam Kaushik, Michael Liss, Ahmed Mansour, San Antonio, TX INTRODUCTION AND OBJECTIVES: Controversy exists regarding the efficacy of partial nephrectomy (PN) in the setting of pathologically upstaged renal cell carcinoma (RCC). We aimed to investigate the predictors of pT3a upstaging as well as survival outcomes in the setting of partial versus radical nephrectomy (RN).
METHODS: We investigated the National Cancer Database (NCDB) for patients with cT1-2 N0M0 RCC who underwent RN or PN. Patients who were upstaged to pT3a were further identified and stratified according to clinical stage and surgical procedure. Multivariate logistic regression analysis was fitted to identify independent predictors of pathological upstaging. Kaplan-Meier analysis with log rank test was performed to evaluate overall survival (OS) among different groups.
RESULTS: Between 2004 to 2015, 180,981 patients with cT1-2 N0M0 RCC who underwent RN or PN were identified in the NCDB. Of them, 11,828 (6.54%) patients were upstaged to pT3a postoperatively.
Predictors of upstaging on multivariate analysis were male gender, cT2 stage and having radical nephrectomy.
Five-year OS for cT1 upstaged patients who underwent PN vs RN was 83.8 % vs 67.3% (95% CI, 81.1-86.2 and 65.4-69.2, respectively) (p<0.001). While among cT2 upstaged group 67.0% vs 65.0% (95% CI, 56.5-74.9 and 63.0-66.9, (p 0.33) respectively) Figure 1 .
Cox proportional hazard modeling identified advancing age, cT2 stage and non-Hispanic ethnicity as independent predictors of OS.
CONCLUSIONS: pT3a upstaging had significant impact on overall survival. PN was not inferior to RN in upstaged patients with initial cT2 disease. Moreover, PN conferred a 5-year survival advantage in patients with initial cT1 disease.
